ProlX Pharmaceuticals Corp. Awarded $4.5 Million in Small Business Innovation Research (SBIR) Grants By the NIH
Posted on: Monday, 31 July 2006, 09:00 CDT
Dr. Lynn Kirkpatrick, CEO and co-founder of ProlX Pharmaceuticals Corp., announced today that the company has been awarded two Phase II Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), totaling more than $4.5 million. The grants support both the Phase II clinical development of ProlX's lead drug candidate, the Trx-1 inhibitor PX-12, as well as the pre-clinical development of the PI3-kinase inhibitor, PX-866.
About the ProlX Pipeline
Trx-1, a growth stimulating redox protein, is over-expressed in a wide variety of human tumors, including colon, gastric and pancreatic cancer. PX-12, a small molecule which blocks the growth-promoting activity of Trx-1, has been evaluated in a Phase I safety study, and is currently being studied in a Phase IB trial for the treatment of gastrointestinal cancers. These trials show that PX-12 is well tolerated, and inhibits its target, Trx-1, producing a clinical benefit at levels well below its maximally tolerated dose. A Phase II clinical trial in pancreatic cancer is scheduled to begin enrolling patients in the next month.
PX-866 is a potent and specific PI3-kinase inhibitor. PI3-kinase plays a major role in the resistance of cancers to normal cell death (apoptosis), and many cancers have a constitutively active PI3-kinase pathway, making it an attractive target for cancer therapies.
"Recent promising pre-clinical data for PX-866 against glioblastoma in animal models indicates how important it is to get this agent into the clinic," said Kirkpatrick. "Currently there is no clinically available inhibitor of PI3-kinase, and this SBIR award will provide the resources needed to move PX-866 forward as quickly as possible to fill that need."
About ProlX Pharmaceuticals
ProlX Pharmaceuticals Corp. is a private biotechnology company located in Tucson, Ariz., and Houston, dedicated to the discovery of novel therapies for the treatment of cancer. The company's small molecule drug pipeline and discovery efforts target redox and survival signaling pathways.
Source: Business Wire
Related Articles
- Celsion Provides Update on Its Global Pivotal Phase III Primary Liver Cancer Trial
- Rexinoid Developed By NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
- Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
- Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
- ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From Its U.S. Phase II/III Clinical Study Of Bepotastine
- GenVec Announces Efficacy Update in Phase II/III Clinical Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer
- Nutra Pharma Announces Final Approval to Begin Phase IIb Human Clinical Trial for the Treatment of Adrenomyeloneuropathy
- Surface Logix Commences Phase I Trial for Novel Gastrointestinal-Specific MTP Inhibitor
- InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
- Dendreon Completes Enrollment in Phase 3 PROTECT (P-11) Clinical Trial of Provenge in Early Stage Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds